Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$-- Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
EV/EBITDA
0
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
2,333,710
CFO
$-31.17 Mln
EBITDA
$-39.37 Mln
Net Profit
$-36.86 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Artelo Biosciences Inc. Warrant (ARTLW)
| -86.0 | -63.9 | -71.0 | -93.8 | -74.3 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
|---|---|
|
Artelo Biosciences Inc. Warrant (ARTLW)
| -0.3 |
|
S&P Small-Cap 600
| 13.9 |
|
BSE Sensex
| 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Artelo Biosciences Inc. Warrant (ARTLW)
|
0.0 | 0.0 | -- | -- | -- | -- | -- | 0.0 |
| 1.5 | 5.2 | 3.6 | 30.3 | -1,439.5 | 31.6 | 0.2 | 0.6 |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid... G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California. Read more
President, CEO, CFO, Treasurer, Secretary & Director
Mr. Gregory D. Gorgas M.B.A.
President, CEO, CFO, Treasurer, Secretary & Director
Mr. Gregory D. Gorgas M.B.A.
Headquarters
Solana Beach, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Artelo Biosciences Inc Warrant (ARTLW) is $0.01 (NASDAQ) as of 17-Jun-2024 16:00 EDT. Artelo Biosciences Inc Warrant (ARTLW) has given a return of -74.3% in the last 3 years.
Since, TTM earnings of Artelo Biosciences Inc Warrant (ARTLW) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Artelo Biosciences Inc Warrant (ARTLW) are Rs -- and Rs -- as of 03-Apr-2026.
Artelo Biosciences Inc Warrant (ARTLW) has a market capitalisation of $ 0 Mln as on 17-Jun-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Artelo Biosciences Inc Warrant (ARTLW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.